Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 21, 2009

Roche and Sigma-Aldrich to Co-Market Complementary Platforms for Epigenetic Research

  • Roche NimbleGen is aligning its ChIP-chip high-density microarrays with Sigma-Aldrich’s GenomePlex. The companies will co-market these complementary technologies.

    To facilitate the ChIP-chip workflow, Roche NimbleGen and Sigma-Aldrich will publish protocols for such research and provide technical support to investigators integrating the two technologies.

    The technologies from Sigma-Aldrich and Roche NimbleGen reportedly facilitate effective ChIP-chip research by addressing two critical bottlenecks in the workflow: efficient amplification of targeted sections of DNA and high-resolution microarray detection. GenomePlex can amplify targeted DNA fragments that are smaller than 200 bp in an efficient and unbiased manner, according to Sigma-Aldrich. The amplified genome can then be analyzed on Roche NimbleGen’s high-density (up to 2.1 million probes per array), long oligonucleotide,ChIP-chip arrays.

    Together, the platforms enable researchers to study the entire genome for epigenetic interactions between DNA and DNA-binding proteins to determine regions of the genome that are transcriptionally active or repressed and the mechanisms that regulate these processes.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »